针对AXL激酶免疫细胞群的动态变化减少实验MASH中的肝炎和纤维化
Sturla Magnus Grøndal1, Anna Tutusaus2,3, Loreto Boix3
1Department of Biomedicine, Centre for Cancer Biomarkers, University of Bergen, Bergen, Norway.
Frontiers in immunology
|May 31, 2024
概括
可溶性AXL (sAXL) 表示代谢功能障碍相关的脂肪肝炎 (MASH) 的进展. 用bemcentinib抑制AXL减少了炎症,并通过调节免疫细胞促进肝脏愈合,提供了潜在的MASH治疗.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 代谢功能障碍相关的脂肪肝炎 (MASH) 是一个严重的未满足的医疗需求,治疗选择有限.
- 由GAS6激活的AXL受体氨酸激酶信号,通过促进肝星细胞激活和炎症性巨细胞反应,加剧MASH.
- 了解MASH相关的细胞变化和AXL抑制的影响对于开发新疗法至关重要.
研究的目的:
- 为了确定受MASH进展影响的特定细胞子集.
- 在MASH模型中评估AXL激酶抑制的治疗潜力.
- 研究可溶性AXL (sAXL) 作为MASH生物标志物的作用.
主要方法:
- 在使用富含脂肪饮食的小鼠中诱导MASH.
- 小分子AXL激酶抑制剂贝姆森提尼布被使用.
- 使用飞行时间质细胞计 (CyTOF) 和机器学习分析了肝细胞群.
- 评估了基因表达和血细胞因子概况.
主要成果:
- 血SAXL水平升高与MASH进展相关,特别是在炎症存在时,作为早期指标.
- 贝姆森蒂尼布治疗减少了促炎反应和改变了免疫细胞群,包括库普弗细胞,单细胞/巨细胞和CD8+ T细胞.
- 抑制AXL促进了转向组织内存T细胞和调节与炎症和肝脏修复相关的转录基因通路的转变.
结论:
- 溶性AXL (sAXL) 是监测MASH进展的潜在生物标志物.
- AXL向有效调节肝脏免疫细胞子集,将它们从炎症转移到修复性表型.
- 抑制AXL代表了MASH的有前途的治疗策略,促进纤维化解和器官愈合.
相关概念视频
Liver Regeneration
3.2K
The liver is an important organ in vertebrates that plays an essential role in metabolism. It is also responsible for storing and redistributing nutrients such as carbohydrates, fats, and vitamins in the body. Additionally, the liver releases bile salts which are critical for digesting food and eliminating toxic metabolites from the body.
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are...
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are...
3.2K
The JAK-STAT Signaling Pathway
8.8K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.8K


